Agios Pharmaceuticals Inc (AGIO)
59.07
+3.99
(+7.24%)
USD |
NASDAQ |
Nov 08, 16:00
59.07
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Revenue (TTM): 32.87M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
September 30, 2024 | 32.87M |
June 30, 2024 | 31.31M |
March 31, 2024 | 29.40M |
December 31, 2023 | 26.82M |
September 30, 2023 | 24.03M |
June 30, 2023 | 20.15M |
March 31, 2023 | 19.02M |
December 31, 2022 | 14.24M |
September 30, 2022 | |
June 30, 2022 | |
March 31, 2022 | |
December 31, 2021 | |
September 30, 2021 | |
June 30, 2021 | |
March 31, 2021 | |
December 31, 2020 | |
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | 0.00 |
September 30, 2019 | 112.48M |
June 30, 2019 | 101.66M |
March 31, 2019 | 115.85M |
December 31, 2018 | 94.39M |
Date | Value |
---|---|
September 30, 2018 | 74.17M |
June 30, 2018 | 70.33M |
March 31, 2018 | 41.26M |
December 31, 2017 | 43.01M |
September 30, 2017 | 55.86M |
June 30, 2017 | 53.49M |
March 31, 2017 | 49.12M |
December 31, 2016 | 69.89M |
September 30, 2016 | 53.46M |
June 30, 2016 | 49.96M |
March 31, 2016 | 56.20M |
December 31, 2015 | 59.12M |
September 30, 2015 | 67.54M |
June 30, 2015 | 95.96M |
March 31, 2015 | 91.15M |
December 31, 2014 | 65.36M |
September 30, 2014 | 57.47M |
June 30, 2014 | 29.83M |
March 31, 2014 | 27.69M |
December 31, 2013 | 25.55M |
September 30, 2013 | 25.09M |
June 30, 2013 | 25.09M |
March 31, 2013 | 25.11M |
December 31, 2012 | 25.11M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
--
Minimum
Dec 2019
32.87M
Maximum
Sep 2024
21.98M
Average
24.03M
Median
Sep 2023
Revenue (TTM) Benchmarks
Pfizer Inc | 59.37B |
Regeneron Pharmaceuticals Inc | 13.85B |
Ligand Pharmaceuticals Inc | 133.48M |
ADMA Biologics Inc | 330.24M |
AnaptysBio Inc | 57.17M |